With the continuous development of living standards, obese children are increasing day by day, and obesity is one of the risk factors of nonalcoholic fatty liver disease in children. Children with NAFLD have a higher risk of end-stage liver disease and a higher mortality rate. At present, the disease has become an increasingly serious public health problem, and it has a great impact on the health and prognosis of children in adulthood. Moreover, the pathogenesis of nonalcoholic fatty liver in children is still in an unclear stage. Traditional Chinese medicine has unique advantages in treating this disease. Treating fatty liver with the thinking mode of syndrome differentiation and treatment may provide a new way for the treatment of nonalcoholic fatty liver in children.

Zhang Lixia, Cui Xiang. Research Progress of Children NAFLD in Western Medicine and Traditional Chinese Medicine. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 7: 79-83. https://doi.org/10.25236/AJMHS.2023.040713.

[1] Zhou Xuelian & Fu Junfen. (2018). Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children. China Journal of Practical Pediatrics (07), 487-492. DOI: 10. 19538/J. EK 20187060. 20010000001

[2] Vos, M. B., Abrams, S. H., Barlow, S. E., Caprio, S., Daniels, S. R., Kohli, R., Mouzaki, M., Sathya, P., Schwimmer, J. B., Sundaram, S. S., & Xanthakos, S. A. (2017) . NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Journal of pediatric gastroenterology and nutrition, 64(2), 319–334. https://doi. org/10. 1097/MPG. 0000000000001482

[3] Weiß, J., Rau, M., & Geier, A. (2014). Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Deutsches Arzteblatt international, 111(26), 447–452. https:// doi. org/ 10. 3238/arztebl. 2014. 0447

[4] Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011). Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 9(6), 524–e60. https://doi.org/10.1016/j.cgh.2011.03.020

[5] Anderson, E. L., Howe, L. D., Jones, H. E., Higgins, J. P., Lawlor, D. A., & Fraser, A. (2015). The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PloS one, 10(10), e0140908. https://doi. org/10. 1371/journal. pone. 0140908

[6] Nobili, V., Alisi, A., Newton, K. P., & Schwimmer, J. B. (2016). Comparison of the Phenotype and Approach to Pediatric vs Adult Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 150(8), 1798–1810. https://doi. org/10. 1053/j. gastro. 2016. 03. 009

[7] Welsh, J. A., Karpen, S., & Vos, M. B. (2013). Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. The Journal of pediatrics, 162(3), 496–500. e1. https://doi. org/10. 1016/j. jpeds. 2012. 08. 043

[8] Zhang Wei, Wei Lai. Prevalence of nonalcoholic fatty liver disease in Asia [J]. Chinese Journal of Hepatology, 2013, 21(11):801-804. 

[9] Mencin, A. A., & Lavine, J. E. (2011). Nonalcoholic fatty liver disease in children. Current opinion in clinical nutrition and metabolic care, 14(2), 151–157. https://doi. org/10. 1097/ MCO. 0b013e328342baec

[10] Schwimmer, J. B., Deutsch, R., Kahen, T., Lavine, J. E., Stanley, C., & Behling, C. (2006). Prevalence of fatty liver in children and adolescents. Pediatrics, 118(4), 1388–1393. https://doi. org/ 10. 1542/peds. 2006-1212

[11] Atsawarungruangkit, A., Elfanagely, Y., Pan, J., Anderson, K., Scharfen, J., & Promrat, K. (2021). Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United States' adolescent population. World journal of hepatology, 13(7), 790–803. https://doi. org/10. 4254/wjh. v13. i7. 790

[12] Allen, A. M., Hicks, S. B., Mara, K. C., Larson, J. J., & Therneau, T. M. (2019). The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. Journal of hepatology, 71(6), 1229–1236. https://doi. org/10. 1016/j. jhep. 2019. 08. 018

[13] Feldstein, A. E., Charatcharoenwitthaya, P., Treeprasertsuk, S., Benson, J. T., Enders, F. B., & Angulo, P. (2009). The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut, 58(11), 1538–1544. https://doi. org/10. 1136/gut. 2008. 171280

[14] Simon, T. G., Roelstraete, B., Hartjes, K., Shah, U., Khalili, H., Arnell, H., & Ludvigsson, J. F. (2021). Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. Journal of hepatology, 75(5), 1034–1041. https://doi. org/10. 1016/j. jhep. 2021. 06. 034

[15] Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J. F., Schattenberg,  J. M., Kawaguchi, T., Arrese, M., Valenti, L., Shiha, G., Tiribelli, C., Yki-Järvinen, H., Fan, J. G., Grønbæk, H., Yilmaz, Y., Cortez-Pinto, H., George, J. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of hepatology, 73(1), 202–209. https://doi. org/ 10. 1016/j. jhep. 2020. 03. 039

[16] Utz-Melere, M., Targa-Ferreira, C., Lessa-Horta, B., Epifanio, M., Mouzaki, M., & Mattos, A. A. (2018). Non-Alcoholic Fatty Liver Disease in Children and Adolescents: Lifestyle Change - a Systematic Review and Meta-Analysis. Annals of hepatology, 17(3), 345–354. https://doi. org/ 10. 5604/01. 3001. 0011. 7380

[17] Spahis, S., Alvarez, F., Ahmed, N., Dubois, J., Jalbout, R., Paganelli, M., Grzywacz, K., Delvin, E., Peretti, N., & Levy, E. (2018). Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of nutritional biochemistry, 58, 28–36. https://doi. org/10. 1016/j. jnutbio. 2018. 03. 025

[18] Lavine, J. E., Schwimmer, J. B., Van Natta, M. L., Molleston, J. P., Murray, K. F., Rosenthal, P., Abrams, S. H., Scheimann, A. O., Sanyal, A. J.,  Chalasani, N., Tonascia, J., Ünalp, A., Clark, J. M., Brunt, E. M., Kleiner, D. E., Hoofnagle, J. H., Robuck, P. R.,  & Nonalcoholic Steatohepatitis Clinical Research Network (2011) . Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 305(16), 1659–1668. https://doi. org/10. 1001/jama. 2011. 520

[19] Tilg, H., & Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (Baltimore, Md. ), 52(5), 1836–1846. https://doi. org/10. 1002/hep. 24001

[20] Phung, N., Pera, N., Farrell, G., Leclercq, I., Hou, J. Y., & George, J. (2009). Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. International journal of molecular medicine, 24(2), 171–180. https://doi. org/10. 3892/ijmm_00000220

[21] Liu Shenshen, Xing Yiqing, Wang Ning, Yu Qiaoling & Zeng Leping. (2020). Meta-analysis of the effect of vitamin E on nonalcoholic fatty liver disease in children. Journal of Clinical Hepatobiliary Diseases (07), 1545-1550. 

[22] Hourigan, S. K., Abrams, S., Yates, K., Pfeifer, K., Torbenson, M., Murray, K., Roth, C. L., Kowdley, K., Scheimann, A. O., & NASH CRN (2015). Relation between vitamin D status and nonalcoholic fatty liver disease in children. Journal of pediatric gastroenterology and nutrition, 60(3), 396–404. https://doi. org/10. 1097/MPG. 0000000000000598

[23] Eliades, M., Spyrou, E., Agrawal, N., Lazo, M., Brancati, F. L., Potter, J. J., Koteish, A. A., Clark, J. M., Guallar, E., & Hernaez, R. (2013). Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics, 38(3), 246–254. https://doi. org/10. 1111/apt. 12377

[24] Jiang Xue, Gao Jian, Hong Ze & Zhou Wendi. (2022). Clinical study of vitamin D in the treatment of obese children with nonalcoholic fatty liver disease. China Journal of Child Health (09), 970-974. 

[25] Nobili, V., Putignani, L., Mosca, A., Del Chierico, F., Vernocchi, P., Alisi, A., Stronati, L., Cucchiara, S., Toscano, M., & Drago, L. (2018). Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? Archives of medical science : AMS, 14(1), 81–87. https://doi. org/10. 5114/aoms. 2016. 62150

[26] Çakır, M., Aksel İşbilen, A., Eyüpoğlu, İ., Sağ, E., Örem, A., Mazlum Şen, T., Kaklıkkaya, N., & Kaya, G. (2017). Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease. The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology, 28(5), 377–383. https://doi. org/ 10. 5152/tjg. 2017. 17084

[27] Gao, X., Zhu, Y., Wen, Y., Liu, G., & Wan, C. (2016). Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatology resear ch: the official journal of the Japan Society of Hepatology, 46(12), 1226–1233. https://doi. org/ 10. 1111 /hepr. 12671

[28] Shi, K. Q., Fan, Y. C., Liu, W. Y., Li, L. F., Chen, Y. P., & Zheng, M. H. (2012). Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Molecular biology reports, 39(10), 9715–9722. https://doi. org/10. 1007/s11033-012-1836-0

[29] Hua Peng, Guo Wei, Xue Jingdong, Li Fenping & Cui Xiang. (2020). Clinical evaluation of Jianpi Huazhuo Xiaozhi recipe in treating nonalcoholic steatohepatitis. Journal of Integrated Traditional Chinese and Western Medicine Liver Disease (05), 408-410. 

[30] Cui Xiang, Liu Linglan & Zhang Fengyuan. (2022). Objectives and advantages of TCM in treating metabolic fatty liver disease. Dr. Gan (04), 50. 

[31] Xiang C, Zhang F Y, Li L. Experience of successfully treating a child with severe metabolic-associated fatty liver disease in 12 weeks using traditional Chinese medicine alone[J]. Gastroenterol Hepatol Res, 2021, 3(2): 4.